Budesonide/formoterol combination in COPD: a US perspective

Budesonide/formoterol combination in COPD: a US perspective

Amir Sharafkhaneh1,2, Amarbir S Mattewal1, Vinu M Abraham1, Goutham Dronavalli1, Nicola A Hanania11Section of Pulmonary, Critical Care Medicine and Sleep Medicine, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA; 2Section of Pulmonary, Critical Care Medicine and Sleep Medicin...

Full description

Bibliographic Details
Main Authors:	Amir Sharafkhaneh, Amarbir S Mattewal, Vinu M Abraham, et al
Format:	Article
Language:	English
Published:	Dove Medical Press 2010-10-01
Series:	International Journal of COPD
Online Access:	http://www.dovepress.com/budesonideformoterol-combination-in-copd-a-us-perspective-a5434

Similar Items

Risks of budesonide/formoterol for the treatment of stable COPD: a meta-analysis
by: Tang B, et al.
Published: (2019-04-01)

Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD
by: Calverley PM, et al.
Published: (2016-12-01)

Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments
by: Trudo F, et al.
Published: (2015-09-01)

Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD
by: Nicola A. Hanania, et al.
Published: (2020-04-01)

Some aspects of application of the combination of formoterol and budesonide: what is changed?
by: A. A. Vizel, et al.
Published: (2019-12-01)

Budesonide/formoterol enhances the expression of pro Surfactant Protein-B in lungs of COPD patients.
by: Soo Jung Um, et al.
Published: (2013-01-01)

COMPARATIVE EFFICACY OF INHALED DRUGS FORMOTEROL / BECLOMETHASONE AND FORMOTEROL / BUDESONIDE AND BRONCHIAL ASTHMA
by: V. A. Nikitin, et al.
Published: (2016-03-01)

Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD
by: Martyn R. Partridge, et al.
Published: (2009-08-01)

Adding budesonide to formoterol reduces risk of clinically important deteriorations (CID) in moderate to very severe COPD
by: Bafadhel, M, et al.
Published: (2018)

Controlled trial of budesonide–formoterol as needed for mild asthma
by: Beasley, R, et al.
Published: (2019)

Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD A double-blind, randomised, non-inferiority, parallel-group, multicentre study
by: Andersson Eva, et al.
Published: (2009-02-01)

Inhalation of Budesonide/Formoterol Increases Diaphragm Muscle Contractility
by: Chiyohiko Shindoh, et al.
Published: (2012-01-01)

Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting
by: Perrone V, et al.
Published: (2016-11-01)

Metabolic changes of different high-resolution computed tomography phenotypes of COPD after budesonide–formoterol treatment
by: Wang C, et al.
Published: (2017-12-01)

Exposure-Response and Clinical Outcome Modeling of Inhaled Budesonide/Formoterol Combination in Asthma Patients
by: Hyun-moon Back, et al.
Published: (2020-04-01)

Effect of Switching from Salmeterol/Fluticasone to Formoterol/Budesonide Combinations in Patients with Uncontrolled Asthma
by: Taisuke Akamatsu, et al.
Published: (2012-01-01)

Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting [Corrigendum]
by: Perrone V, et al.
Published: (2017-01-01)

Characteristics of initiators of budesonide/glycopyrrolate/formoterol for treatment of chronic obstructive pulmonary disease (COPD) in the United States: the AURA study
by: Edward C. Portillo, et al.
Published: (2023-04-01)

Budesonide/formoterol combination for reducing cough in COVID-19 patients—A case of inflated expectations!
by: Onkardeep Kaur, et al.
Published: (2023-01-01)

Efficacy of indacaterol 75 &micro;g versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis
by: Cope S, et al.
Published: (2012-07-01)

Bone and ocular safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized study
by: Edward M. Kerwin, et al.
Published: (2019-07-01)

Bronchodilatory effect of inhaled budesonide/formoterol and budesonide/salbutamol in acute asthma: a double-blind, randomized controlled trial
by: Arun Jenish J, et al.
Published: (2012-03-01)

Exacerbations and Real-World Outcomes After Single-Inhaler Triple Therapy of Budesonide/Glycopyrrolate/Formoterol Fumarate, Among Patients with COPD: Results from the EROS (US) Study
by: Strange C, et al.
Published: (2023-10-01)

Effects of treatment with montelukast alone, budesonide/formoterol alone and a combination of both in cough variant asthma
by: Fang Yi, et al.
Published: (2022-10-01)

Evaluation of inhaler technique and achievement and maintenance of mastery of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in adult patients with asthma: the Easy Low Instruction Over Time (ELIOT) study
by: David B. Price, et al.
Published: (2018-06-01)

Clinical experience of using formoterol/budesonide in patients with chronic obstructive pulmonary disease
by: I. V. Demko, et al.
Published: (2021-10-01)

Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating Patients with COPD Receiving Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy
by: Moretz C, et al.
Published: (2020-09-01)

Long-term maintenance of pediatric asthma: focus on budesonide/formoterol inhalation aerosol
by: Peter N Huynh, et al.
Published: (2010-02-01)

Budesonide/glycopyrronium/formoterol fumarate triple therapy prevents pulmonary hypertension in a COPD mouse model via NFκB inactivation
by: Ratoe Suraya, et al.
Published: (2022-06-01)

Pharmacoeconomics analysis of using a fixed combination of budesonide/formoterol in patients with asthma in the health care system of the Russian Federation
by: Sergey K. Zyryanov, et al.
Published: (2022-08-01)

Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler dual therapies in patients with COPD: a sub-study of the ETHOS trial
by: Klaus F. Rabe, et al.
Published: (2021-08-01)

Efficacy of budesonide/formoterol maintenance and reliever therapy compared with higher-dose budesonide as step-up from low-dose inhaled corticosteroid treatment
by: Christine R. Jenkins, et al.
Published: (2017-04-01)

Effect of inhaled budesonide/formoterol fumarate dihydrate delivered via two different devices on lung function in patients with COPD and low peak inspiratory flow
by: Bärbel Huber, et al.
Published: (2022-07-01)

Umeclidinium/Vilanterol Compared with Fluticasone Propionate/Salmeterol, Budesonide/Formoterol, and Tiotropium as Initial Maintenance Therapy in Patients with COPD Who Have High Costs and Comorbidities
by: Kalhan R, et al.
Published: (2021-04-01)

Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol.
by: Pavord, I, et al.
Published: (2009)

Review: Differences in the pharmacodynamics of budesonide/formoterol and salmeterol/fluticasone reflect differences in their therapeutic usefulness in asthma
by: Bertil Lindmark
Published: (2008-10-01)

Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD
by: Ichinose M, et al.
Published: (2019-12-01)

The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial
by: Borgström Lars, et al.
Published: (2009-10-01)

Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Exacerbation Outcomes in Patients with COPD without a Recent Exacerbation History: A Subgroup Analysis of KRONOS
by: Martinez FJ, et al.
Published: (2021-01-01)

A US database study characterizing patients initiating a budesonide–formoterol combination versus tiotropium bromide as initial maintenance therapy for chronic obstructive pulmonary disease
by: Kern DM, et al.
Published: (2014-07-01)